Bioequivalence Study of Vortioxetine 5 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions

The primary objective of this study is to evaluate the **bioequivalence** of Vortioxetine 5 mg film-coated tablets in healthy participants under fasting conditions. Bioequivalence studies are crucial in determining whether a generic version of a drug releases its active ingredient into the bloodstream at the same rate and extent as the original branded drug. This is clinically relevant as it ensures therapeutic equivalence, allowing for the safe substitution of the generic product for the branded one without compromising efficacy or safety.

The clinical trial involves a **study population** that includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial population is noted to include a **vulnerable population**, although specific details regarding the nature of this vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Participants do not have any specific medical conditions as a prerequisite for inclusion in the trial. Information regarding lifestyle considerations such as diet, physical activity, or habits has not been provided. The sponsor has not given detailed information on the selection criteria for the trial population.

The clinical trial is designed to evaluate the **bioequivalence** of Vortioxetine 5 mg film-coated tablets in healthy participants under fasting conditions. This study is a Phase 2 trial, which is categorized as a randomized, double-blind, controlled trial. The estimated recruitment start date is July 15, 2024, with an anticipated end date of September 6, 2024. The trial does not involve any specific medical condition, as it is conducted with healthy participants.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the test or reference formulation of Vortioxetine. The trial will include multiple follow-up visits to monitor the participants' health and collect necessary data to assess the bioequivalence of the formulations. The end-of-study visit will conclude the trial, where final assessments and data collection will occur.

The expected length of participant involvement is approximately two months, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include non-compliance with study procedures, adverse events, or withdrawal of consent by the participant. The trial is conducted under strict adherence to ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be described. The absence of these details limits the ability to provide a comprehensive overview of the treatments involved in the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on July 15, 2024, with an estimated completion date of September 6, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters, adhering to the standards expected in clinical research. The trial's design and execution will ensure that the data collected is robust and reliable, contributing to the understanding of the treatment's efficacy in the specified medical condition. The trial phase indicates a focus on further evaluating the treatment's effectiveness and safety profile, building on initial findings from earlier phases.